PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25427746-0	2016	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.	rupatadine	81-91	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
27758758-2	2017	Rupatadine is an antihistamine with a demonstrated anti-PAF effect, although its capacity to inhibit PAF-induced MC degranulation has not been fully evaluated.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	56-59
27758758-2	2017	Rupatadine is an antihistamine with a demonstrated anti-PAF effect, although its capacity to inhibit PAF-induced MC degranulation has not been fully evaluated.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	101-104
27758758-3	2017	Objectives: To compare the ability of rupatadine to inhibit PAF-induced MC degranulation with that of desloratadine and levocetirizine and to confirm the dual anti-H1 and anti-PAF activity of rupatadine.	rupatadine	38-48	PCNA clamp associated factor	Homo sapiens	60-63
27758758-3	2017	Objectives: To compare the ability of rupatadine to inhibit PAF-induced MC degranulation with that of desloratadine and levocetirizine and to confirm the dual anti-H1 and anti-PAF activity of rupatadine.	rupatadine	192-202	PCNA clamp associated factor	Homo sapiens	176-179
27758758-9	2017	RESULTS: CV6209 and rupatadine inhibited PAF-induced MC degranulation in both LAD2 and hLMCs.	rupatadine	20-30	PCNA clamp associated factor	Homo sapiens	41-44
27758758-10	2017	In LAD2, rupatadine (5 and 10 microM) and levocetirizine (5 microM), but not desloratadine, inhibited PAF-induced b-hexosaminidase release.	rupatadine	9-19	PCNA clamp associated factor	Homo sapiens	102-105
27758758-11	2017	Rupatadine (1-10 microM), levocetirizine (1-10 microM), and desloratadine (10 microM) inhibited PAF-induced histamine release.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	96-99
27758758-13	2017	CONCLUSIONS: This study shows that rupatadine and, to a lesser extent, levocetirizine, but not desloratadine, inhibit PAF-induced degranulation in both LAD2 and hLMCs.	rupatadine	35-45	PCNA clamp associated factor	Homo sapiens	118-121
27758758-14	2017	These findings support the dual antihistamine and anti-PAF effect of rupatadine in allergic disorders.	rupatadine	69-79	PCNA clamp associated factor	Homo sapiens	55-58
25427746-0	2016	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.	rupatadine	81-91	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
25427746-1	2016	Rupatadine (RUP) is an oral antihistamine and platelet-activating factor antagonist and is shown as the substrate of CYP3A5 and P-gp.	rupatadine	0-10	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	117-123
25427746-1	2016	Rupatadine (RUP) is an oral antihistamine and platelet-activating factor antagonist and is shown as the substrate of CYP3A5 and P-gp.	rupatadine	0-10	phosphoglycolate phosphatase	Homo sapiens	128-132
26267219-2	2016	This study reports the efficacy and safety of rupatadine, a modern H1 and PAF antagonist recently authorized in Europe for children with allergic rhinitis and CSU.	rupatadine	46-56	PCNA clamp associated factor	Homo sapiens	74-77
25521304-5	2015	Rupatadine, a newer antihistaminic, has PAF receptor antagonist activity and has shown anti-TNF-alpha activity in vitro.	rupatadine	0-10	tumor necrosis factor	Homo sapiens	92-101
25443720-0	2014	Rupatadine effectively prevents the histamine-induced up regulation of histamine H1R and bradykinin B2R receptor gene expression in the rat paw.	rupatadine	0-10	histamine receptor H 1	Rattus norvegicus	81-84
25443720-10	2014	CONCLUSION: Rupatadine has a suppressing effect on H1R and B2R gene expression which could add to its efficacy towards allergy and allergy-like conditions.	rupatadine	12-22	histamine receptor H 1	Rattus norvegicus	51-62
26120520-0	2014	Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	69-72
24267366-0	2013	Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	129-155
24499312-2	2013	We aimed to assess the anti-PAF effects of rupatadine and levocetirizine in the upper airways.	rupatadine	43-53	PCNA clamp associated factor	Homo sapiens	28-31
24499312-5	2013	In SAR patients but not in HV, both rupatadine and levocetirizine showed a trend to decrease PAF-induced T4SS from 60 to 120 minutes.	rupatadine	36-46	PCNA clamp associated factor	Homo sapiens	93-96
24499312-8	2013	CONCLUSIONS: These results suggest that both rupatadine and levocetirizine showed a tendency decrease toward nasal symptoms, but only rupatadine significally reduces the overall nasal symptoms (AUC) induced by PAF in SAR patients.	rupatadine	134-144	PCNA clamp associated factor	Homo sapiens	210-213
20713756-9	2010	In the rupatadine group there was a significantly higher reduction (P = .004) in IgE level and Total Nasal Symptom Score (P < .001) compared with the levocetirizine group.	rupatadine	7-17	immunoglobulin heavy constant epsilon	Homo sapiens	81-84
23826741-2	2013	Rupatadine, a molecule with intense antihistaminic activity and with antagonist PAF effects through its interaction with specific receptors, is indicated for the treatment of intermittent or persistent allergic rhinitis and urticaria.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	80-83
23869224-0	2013	Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	62-65
23869224-2	2013	We investigated the potential therapeutic efficacy and mechanism of rupatadine, a dual antagonist of histamine and platelet-activation factor (PAF), in bleomycin- (BLM-) and silica-induced pulmonary fibrosis.	rupatadine	68-78	PCNA clamp associated factor	Homo sapiens	115-141
23869224-2	2013	We investigated the potential therapeutic efficacy and mechanism of rupatadine, a dual antagonist of histamine and platelet-activation factor (PAF), in bleomycin- (BLM-) and silica-induced pulmonary fibrosis.	rupatadine	68-78	PCNA clamp associated factor	Homo sapiens	143-146
23869224-9	2013	The anti-fibrotic action of rupatadine might relate to its attenuation of BLM- or PAF-induced premature senescence because rupatadine treatment protected against the in vivo and in vitro activation of the p53/p21-dependent senescence pathway.	rupatadine	28-38	PCNA clamp associated factor	Homo sapiens	82-85
23869224-9	2013	The anti-fibrotic action of rupatadine might relate to its attenuation of BLM- or PAF-induced premature senescence because rupatadine treatment protected against the in vivo and in vitro activation of the p53/p21-dependent senescence pathway.	rupatadine	28-38	tumor protein p53	Homo sapiens	205-208
23869224-9	2013	The anti-fibrotic action of rupatadine might relate to its attenuation of BLM- or PAF-induced premature senescence because rupatadine treatment protected against the in vivo and in vitro activation of the p53/p21-dependent senescence pathway.	rupatadine	28-38	H3 histone pseudogene 16	Homo sapiens	209-212
23869224-9	2013	The anti-fibrotic action of rupatadine might relate to its attenuation of BLM- or PAF-induced premature senescence because rupatadine treatment protected against the in vivo and in vitro activation of the p53/p21-dependent senescence pathway.	rupatadine	123-133	tumor protein p53	Homo sapiens	205-208
23869224-9	2013	The anti-fibrotic action of rupatadine might relate to its attenuation of BLM- or PAF-induced premature senescence because rupatadine treatment protected against the in vivo and in vitro activation of the p53/p21-dependent senescence pathway.	rupatadine	123-133	H3 histone pseudogene 16	Homo sapiens	209-212
23869224-10	2013	Our studies indicate that rupatadine promotes the resolution of pulmonary inflammation and fibrosis by attenuating the PAF-mediated senescence response.	rupatadine	26-36	PCNA clamp associated factor	Homo sapiens	119-122
22134570-9	2011	In rupatadine group, there was 27.9 percent decrease (P=0.027) in DC eosinophil, 35.6 percent decrease (P=0.036) in AEC, 15.3 percent decrease (P=0.024) in serum IgE, 28.2 percent decrease (P=0.02) in Total Symptom Scoring, and 27.3 percent decrease (P=0.006) in Aerius Quality of Life Questionnaire score.	rupatadine	3-13	immunoglobulin heavy constant epsilon	Homo sapiens	162-165
19672095-4	2010	METHODS: Rupatadine (1-50 microM) was used before stimulation by: (1) interleukin (IL)-1 to induce IL-6 from human leukemic mast cells (HMC-1 cells), (2) substance P for histamine, IL-8 and vascular endothelial growth factor release from LAD2 cells, and (3) IgE/anti-IgE for cytokine release from human cord blood-derived cultured mast cells.	rupatadine	9-19	interleukin 6	Homo sapiens	99-103
19672095-4	2010	METHODS: Rupatadine (1-50 microM) was used before stimulation by: (1) interleukin (IL)-1 to induce IL-6 from human leukemic mast cells (HMC-1 cells), (2) substance P for histamine, IL-8 and vascular endothelial growth factor release from LAD2 cells, and (3) IgE/anti-IgE for cytokine release from human cord blood-derived cultured mast cells.	rupatadine	9-19	C-X-C motif chemokine ligand 8	Homo sapiens	181-185
19672095-4	2010	METHODS: Rupatadine (1-50 microM) was used before stimulation by: (1) interleukin (IL)-1 to induce IL-6 from human leukemic mast cells (HMC-1 cells), (2) substance P for histamine, IL-8 and vascular endothelial growth factor release from LAD2 cells, and (3) IgE/anti-IgE for cytokine release from human cord blood-derived cultured mast cells.	rupatadine	9-19	vascular endothelial growth factor A	Homo sapiens	190-224
19672095-6	2010	RESULTS: Rupatadine (10-50 microM) inhibited IL-6 release (80% at 50 microM) from HMC-1 cells, whether added 10 min or 24 h prior to stimulation.	rupatadine	9-19	interleukin 6	Homo sapiens	45-49
19672095-7	2010	Rupatadine (10-50 microM for 10 min) inhibited IL-8 (80%), vascular endothelial growth factor (73%) and histamine (88%) release from LAD2 cells, as well as IL-6, IL-8, IL-10, IL-13 and tumor necrosis factor release from human cord blood-derived cultured mast cells.	rupatadine	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	47-51
19672095-7	2010	Rupatadine (10-50 microM for 10 min) inhibited IL-8 (80%), vascular endothelial growth factor (73%) and histamine (88%) release from LAD2 cells, as well as IL-6, IL-8, IL-10, IL-13 and tumor necrosis factor release from human cord blood-derived cultured mast cells.	rupatadine	0-10	vascular endothelial growth factor A	Homo sapiens	59-93
19672095-7	2010	Rupatadine (10-50 microM for 10 min) inhibited IL-8 (80%), vascular endothelial growth factor (73%) and histamine (88%) release from LAD2 cells, as well as IL-6, IL-8, IL-10, IL-13 and tumor necrosis factor release from human cord blood-derived cultured mast cells.	rupatadine	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	162-166
19672095-7	2010	Rupatadine (10-50 microM for 10 min) inhibited IL-8 (80%), vascular endothelial growth factor (73%) and histamine (88%) release from LAD2 cells, as well as IL-6, IL-8, IL-10, IL-13 and tumor necrosis factor release from human cord blood-derived cultured mast cells.	rupatadine	0-10	interleukin 10	Homo sapiens	168-173
19672095-7	2010	Rupatadine (10-50 microM for 10 min) inhibited IL-8 (80%), vascular endothelial growth factor (73%) and histamine (88%) release from LAD2 cells, as well as IL-6, IL-8, IL-10, IL-13 and tumor necrosis factor release from human cord blood-derived cultured mast cells.	rupatadine	0-10	interleukin 13	Homo sapiens	175-180
17520822-8	2007	The OA-induced elevation of arterial blood oxygen pressure was inhibited, as well as PAF, ICAM-1, IL-8 in BALF in rupatadine group.	rupatadine	114-124	ICAM-1	Oryctolagus cuniculus	90-96
19893935-3	2009	Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist.	rupatadine	0-10	histamine receptor H1	Homo sapiens	75-96
17520822-8	2007	The OA-induced elevation of arterial blood oxygen pressure was inhibited, as well as PAF, ICAM-1, IL-8 in BALF in rupatadine group.	rupatadine	114-124	interleukin-8	Oryctolagus cuniculus	98-102
10959557-9	2000	CONCLUSIONS: Rupatadine and loratadine showed similar inhibitory effect on histamine and TNF-alpha release, whereas SR-27417A only exhibited inhibitory effect against TNF-alpha.	rupatadine	13-23	tumor necrosis factor	Homo sapiens	89-98
17335300-1	2007	Rupatadine (Rupafin, Rinialer, Rupax, Alergoliber) is a selective oral histamine H(1)-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro.	rupatadine	0-10	histamine receptor H1	Homo sapiens	71-94
12944997-0	2003	Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist.	rupatadine	0-10	histamine receptor H1	Homo sapiens	28-49
10959557-0	2000	In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1.	rupatadine	30-40	tumor necrosis factor	Canis lupus familiaris	58-67
8996188-0	1997	Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).	rupatadine	0-10	patchy fur	Mus musculus	73-99
10959557-1	2000	OBJECTIVE AND DESIGN: To examine the inhibitory potential of rupatadine, a new H1-antihistamine and anti-PAF agent, on histamine and TNF-alpha release.	rupatadine	61-71	tumor necrosis factor	Homo sapiens	133-142
10959557-8	2000	Rupatadine, loratadine and SR-27417A inhibited TNF-alpha release with IC50 2.0+/-0.9 microM, 2.1+/-1.1 M and 4.3+/-0.6 microM, respectively.	rupatadine	0-10	tumor necrosis factor	Homo sapiens	47-56
10556945-0	1999	Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels.	rupatadine	11-21	potassium voltage-gated channel subfamily A member 5	Homo sapiens	117-122
10556945-2	1999	The effects of rupatadine, a new dual antagonist of both histamine H1 and platelet-activating factor receptors, were studied on human cloned hKv1.5 channels expressed in Ltk- cells using the whole-cell patch-clamp technique.	rupatadine	15-25	potassium voltage-gated channel subfamily A member 5	Homo sapiens	141-147
10556945-4	1999	Rupatadine produced a use- and concentration-dependent block of hKv1.5 channels (KD=2.4+/-0.7 micronM) and slowed the deactivation of the tail currents, thus inducing the "crossover" phenomenon.	rupatadine	0-10	potassium voltage-gated channel subfamily A member 5	Homo sapiens	64-70
10556945-8	1999	Moreover, rupatadine also modified the voltage-dependence of hKv1.5 channel activation, which exhibited two components, the midpoint of the steeper component averaging -25.	rupatadine	10-20	potassium voltage-gated channel subfamily A member 5	Homo sapiens	61-67
10556945-17	1999	All these results suggest that rupatadine blocks hKv1.5 channels binding to an external and to an internal binding site but only at concentrations much higher than therapeutic plasma levels in man.	rupatadine	31-41	potassium voltage-gated channel subfamily A member 5	Homo sapiens	49-55
8996188-0	1997	Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).	rupatadine	0-10	patchy fur	Mus musculus	101-104
8996188-4	1997	Rupatadine blocked histamine- and PAF-induced effects in vivo, such as hypotension in rats (ID50 = 1.4 and 0.44 mg/kg i.v., respectively) and bronchoconstriction in guinea pigs (ID50 = 113 and 9.6 micrograms/kg i.v.).	rupatadine	0-10	PCNA clamp associated factor	Rattus norvegicus	34-37
8996188-7	1997	Rupatadine"s duration of action was long, as assessed by the histamine- and PAF-induced increase in vascular permeability test in dogs (42 and 34% inhibition at 26 h after 1 mg/kg p.o.).	rupatadine	0-10	PCNA clamp associated factor	Rattus norvegicus	76-79
8996188-10	1997	Overall, rupatadine combines histamine and PAF antagonist activities in vivo with high potency, the antihistamine properties being similar to or higher than those of loratadine, whereas rupatadine"s PAF antagonist effects were near those of WEB-2066.	rupatadine	9-19	patchy fur	Mus musculus	43-46
8996188-10	1997	Overall, rupatadine combines histamine and PAF antagonist activities in vivo with high potency, the antihistamine properties being similar to or higher than those of loratadine, whereas rupatadine"s PAF antagonist effects were near those of WEB-2066.	rupatadine	186-196	patchy fur	Mus musculus	199-202
8996188-11	1997	Rupatadine is therefore a good candidate for further development in the treatment of allergic and inflammatory conditions in which both PAF and histamine are implicated.	rupatadine	0-10	patchy fur	Mus musculus	136-139
34747284-8	2021	Rupatadine pretreatment reduced the previously mentioned parameters, preserved a nearly normal intestinal mucosa picture with replenished GSH and elevated IL-10.	rupatadine	0-10	interleukin 10	Rattus norvegicus	155-160
34218304-8	2021	Rupatadine significantly reduced all measured parameters (P < 0.05) except for IL-17 and CLU.	rupatadine	0-10	interleukin 17A	Homo sapiens	79-84
34218304-8	2021	Rupatadine significantly reduced all measured parameters (P < 0.05) except for IL-17 and CLU.	rupatadine	0-10	clusterin	Homo sapiens	89-92
34747284-9	2021	In conclusion, rupatadine is a dual histamine receptor 1, and a PAF blocker could reduce 5-FU-induced oxidative damage, inflammation, apoptosis, and ulceration of the intestinal epithelium.	rupatadine	15-25	PCNA clamp associated factor	Rattus norvegicus	64-67
35050802-4	2022	Rupatadine is a potent histamine receptor 1 (H1R) and platelet-activating factor (PAF) blocker.	rupatadine	0-10	histamine receptor H 1	Rattus norvegicus	45-48
34571986-0	2021	The Platelet-Activating Factor Receptor"s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.	rupatadine	133-143	platelet activating factor receptor	Homo sapiens	4-39
34571986-8	2021	The clinically approved PAFR antagonist rupatadine effectively inhibited in vitro cell proliferation and migration of ovarian cancer cells.	rupatadine	40-50	platelet activating factor receptor	Homo sapiens	24-28
34571986-9	2021	PAFR is a prognostic marker in ovarian cancer patients and its inhibition through rupatadine may have important therapeutic implications in the therapy of ovarian cancer patients.	rupatadine	82-92	platelet activating factor receptor	Homo sapiens	0-4
35119631-0	2022	Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats.	rupatadine	82-92	heme oxygenase 1	Rattus norvegicus	39-43
35119631-9	2022	RU ameliorated 5-FU-induced liver damage as proved by the improved serum ALT, AST, and hepatic oxidative stress parameters, the attenuated expression of hepatic pro-inflammatory cytokines and PAF, and the up-regulation of HO-1.	rupatadine	0-2	heme oxygenase 1	Rattus norvegicus	222-226
35050802-4	2022	Rupatadine is a potent histamine receptor 1 (H1R) and platelet-activating factor (PAF) blocker.	rupatadine	0-10	PCNA clamp associated factor	Rattus norvegicus	54-80
35050802-4	2022	Rupatadine is a potent histamine receptor 1 (H1R) and platelet-activating factor (PAF) blocker.	rupatadine	0-10	PCNA clamp associated factor	Rattus norvegicus	82-85
35050802-10	2022	Rupatadine reduced the oxidative damage and the levels of proinflammatory cytokines, PAF, histamine, myeloperoxidase, NF-kappaB, and caspase 3 expressions.	rupatadine	0-10	PCNA clamp associated factor	Rattus norvegicus	85-88
35050802-10	2022	Rupatadine reduced the oxidative damage and the levels of proinflammatory cytokines, PAF, histamine, myeloperoxidase, NF-kappaB, and caspase 3 expressions.	rupatadine	0-10	myeloperoxidase	Rattus norvegicus	101-116
35050802-10	2022	Rupatadine reduced the oxidative damage and the levels of proinflammatory cytokines, PAF, histamine, myeloperoxidase, NF-kappaB, and caspase 3 expressions.	rupatadine	0-10	caspase 3	Rattus norvegicus	133-142
33296106-7	2020	The histamine-1 receptor antagonist rupatadine was developed to have anti-PAF activity, and also inhibits activation of human mast cells in response to PAF.	rupatadine	36-46	PCNA clamp associated factor	Homo sapiens	74-77
33995066-0	2021	Boosting Akt Pathway by Rupatadine Modulates Th17/Tregs Balance for Attenuation of Isoproterenol-Induced Heart Failure in Rats.	rupatadine	24-34	AKT serine/threonine kinase 1	Rattus norvegicus	9-12
33995066-3	2021	It also explored the role of PI3k/Akt as a possible mechanistic pathway, through which rupatadine could modulate Th17/Tregs balance to display its effect.	rupatadine	87-97	AKT serine/threonine kinase 1	Rattus norvegicus	34-37
33995066-6	2021	Moreover, rupatadine prevented the marked elevation of PAF and oxidative stress in addition to Th17 promoting cytokines (IL-6, IL-23, and TGF-beta).	rupatadine	10-20	interleukin 6	Rattus norvegicus	121-125
33995066-6	2021	Moreover, rupatadine prevented the marked elevation of PAF and oxidative stress in addition to Th17 promoting cytokines (IL-6, IL-23, and TGF-beta).	rupatadine	10-20	transforming growth factor alpha	Rattus norvegicus	138-146
33995066-7	2021	Accordingly, rupatadine prevented Th17 stimulation or expansion as indicated by increased Foxp3/RORgammat ratio and decreased production of its pro-inflammatory cytokine (IL-17).	rupatadine	13-23	forkhead box P3	Rattus norvegicus	90-95
33995066-7	2021	Accordingly, rupatadine prevented Th17 stimulation or expansion as indicated by increased Foxp3/RORgammat ratio and decreased production of its pro-inflammatory cytokine (IL-17).	rupatadine	13-23	interleukin 17A	Rattus norvegicus	171-176
33995066-8	2021	Rupatadine treatment mitigated isoproterenol-induced activation of STAT-3 signaling and the imbalance in p-Akt/total Akt ratio affording marked decrease in atrogin-1 and apoptotic biomarkers.	rupatadine	0-10	signal transducer and activator of transcription 3	Rattus norvegicus	67-73
33995066-8	2021	Rupatadine treatment mitigated isoproterenol-induced activation of STAT-3 signaling and the imbalance in p-Akt/total Akt ratio affording marked decrease in atrogin-1 and apoptotic biomarkers.	rupatadine	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	107-110
33995066-8	2021	Rupatadine treatment mitigated isoproterenol-induced activation of STAT-3 signaling and the imbalance in p-Akt/total Akt ratio affording marked decrease in atrogin-1 and apoptotic biomarkers.	rupatadine	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	117-120
33995066-8	2021	Rupatadine treatment mitigated isoproterenol-induced activation of STAT-3 signaling and the imbalance in p-Akt/total Akt ratio affording marked decrease in atrogin-1 and apoptotic biomarkers.	rupatadine	0-10	F-box protein 32	Rattus norvegicus	156-165
33995066-11	2021	In conclusion, rupatadine could be an effective therapy against the development of isoproterenol-induced heart failure where PI3K/Akt pathway seems to play a crucial role in its protective effect.	rupatadine	15-25	AKT serine/threonine kinase 1	Rattus norvegicus	130-133
33296106-7	2020	The histamine-1 receptor antagonist rupatadine was developed to have anti-PAF activity, and also inhibits activation of human mast cells in response to PAF.	rupatadine	36-46	PCNA clamp associated factor	Homo sapiens	152-155
33296106-8	2020	Rupatadine could be repurposed for COVID-19 prophylaxis alone or together with other PAF-inhibitors of natural origin such as the flavonoids quercetin and luteolin, which have antiviral, anti-inflammatory, and anti-PAF actions.	rupatadine	0-10	PCNA clamp associated factor	Homo sapiens	215-218
33084462-8	2020	At T7, aprepitant displayed higher improvements than rupatadine (itch-VAS= 4[3-5] vs 8.5[8-9], p< 0.01, DLQI= 14[13-16] vs. 18[16-21], p < 0.01 and ESS= 5[4-7] vs 15[14-16], p < 0.01).	rupatadine	53-63	itchy E3 ubiquitin protein ligase	Homo sapiens	65-69
33084462-9	2020	Doubling the rupatadine dosage from 10mg to 20mg/day only slightly improve itch (itch-VAS 9[8-10] vs 9[8-9], p = 0.03), conversely no modifications in the quality of life (DLQI 18[17-20] vs 18[17-21], p = 0.73) and increased sleepiness (ESS 10[9-11] vs 15[14-16], <0.01).	rupatadine	13-23	itchy E3 ubiquitin protein ligase	Homo sapiens	75-79
33084462-9	2020	Doubling the rupatadine dosage from 10mg to 20mg/day only slightly improve itch (itch-VAS 9[8-10] vs 9[8-9], p = 0.03), conversely no modifications in the quality of life (DLQI 18[17-20] vs 18[17-21], p = 0.73) and increased sleepiness (ESS 10[9-11] vs 15[14-16], <0.01).	rupatadine	13-23	itchy E3 ubiquitin protein ligase	Homo sapiens	81-85
31470575-5	2019	However, rupatadine, a second-generation antihistamine with dual antihistamine and anti-PAF effects has shown promising results by both blocking nasal symptoms and inhibiting mast cell activation induced by PAF, in comparison to antihistamine receptor drugs.	rupatadine	9-19	PCNA clamp associated factor	Homo sapiens	88-91
31470575-5	2019	However, rupatadine, a second-generation antihistamine with dual antihistamine and anti-PAF effects has shown promising results by both blocking nasal symptoms and inhibiting mast cell activation induced by PAF, in comparison to antihistamine receptor drugs.	rupatadine	9-19	PCNA clamp associated factor	Homo sapiens	207-210
31274307-0	2019	Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine.	rupatadine	94-104	histamine receptor H1	Homo sapiens	41-62
31274307-2	2019	We show that both rupatadine (1) and desloratadine (2) have a long residence time at the histamine H1 receptor (H1R).	rupatadine	18-28	histamine receptor H1	Homo sapiens	89-110
31274307-2	2019	We show that both rupatadine (1) and desloratadine (2) have a long residence time at the histamine H1 receptor (H1R).	rupatadine	18-28	histamine receptor H1	Homo sapiens	112-115
30863716-2	2019	For alleviation of allergic symptoms, H1R antagonists are therapeutic drugs; of which the most frequently prescribed are second generation drugs, such as; Cetirizine, Loratadine, Hydroxyzine, Desloratadine, Bepotastine, Acrivastine and Rupatadine.	rupatadine	236-246	histamine receptor H1	Homo sapiens	38-41
29088819-8	2017	Moreover, the antagonism of PAFR by rupatadine, a prescription PAFR inhibitor, protected against the development of emphysema, and reduced the autophagic death of neutrophils after CS exposure.	rupatadine	36-46	platelet-activating factor receptor	Mus musculus	28-32
29088819-8	2017	Moreover, the antagonism of PAFR by rupatadine, a prescription PAFR inhibitor, protected against the development of emphysema, and reduced the autophagic death of neutrophils after CS exposure.	rupatadine	36-46	platelet-activating factor receptor	Mus musculus	63-67